Musings from Kyoto Japan, mostly on Mushrooms, Food, Travel and the like

Latest

Wall Street Journal – OMRON and Building an Inclusive Society

Here’s a link to an interview I did recently with OMRON America’s Tim Hill, OMRON Latin America’s Yolanda Bolanos, Teng Zeng at OMRON Robotics and Caroline Casey, Founder of the Valuable 500. It was a pleasure to interview such committed supporters of DEI and people with disabilities worldwide. https://partners.wsj.com/omron/innovating-for-tomorrow/building-an-inclusive-society-to-unlock-human-creativity It is free to read for all.

At the WSJ page, you can click on certain segments of the interview to hear the speakers in more detail. Below is a taster of the full text.

According to the Valuable 500—an international collective of CEOs committed to ending disability exclusion—one-in-five people experience disability in some form. In the U.S., this figure rises to one in four. Despite the enormity of the issue and global progress on this front, professional opportunities for disabled workers remain severely limited in some countries and sectors.

“In my view, DEI is about nurturing diverse perspectives, giving equal importance to each opinion and creating a workplace where everyone can express themselves,” says Christina Connelly, VP of Human Resources at OMRON Americas and Executive Sponsor of its DEI Workgroup.

Connelly explains that as firm supporters of equitable practices for over five decades, the global technology leader “brings together people with different abilities, personalities and perspectives, and empowers them to take on challenges while creating value for society.”

Understanding that DEI efforts require ongoing discussion, four experts from around the world came together to share the challenges, outcomes and hopes associated with inclusive integration. The following conversation features Tim Hill, Head of Stakeholder Engagement at OMRON Americas; Yolanda Bolaños, HR Director at OMRON Latin America & Canada; Teng Zhang, HR Manager at OMRON Robotics & Safety Technologies Inc.; and Caroline Casey, Founder of the Valuable 500.

According to the Valuable 500—an international collective of CEOs committed to ending disability exclusion—one-in-five people experience disability in some form. In the U.S., this figure rises to one in four. Despite the enormity of the issue and global progress on this front, professional opportunities for disabled workers remain severely limited in some countries and sectors.

“In my view, DEI is about nurturing diverse perspectives, giving equal importance to each opinion and creating a workplace where everyone can express themselves,” says Christina Connelly, VP of Human Resources at OMRON Americas and Executive Sponsor of its DEI Workgroup.

Connelly explains that as firm supporters of equitable practices for over five decades, the global technology leader “brings together people with different abilities, personalities and perspectives, and empowers them to take on challenges while creating value for society.”

Understanding that DEI efforts require ongoing discussion, four experts from around the world came together to share the challenges, outcomes and hopes associated with inclusive integration. The following conversation features Tim Hill, Head of Stakeholder Engagement at OMRON Americas; Yolanda Bolaños, HR Director at OMRON Latin America & Canada; Teng Zhang, HR Manager at OMRON Robotics & Safety Technologies Inc.; and Caroline Casey, Founder of the Valuable 500.

How can companies ensure the voices of disabled employees are consistently spotlighted?

CC: First, I want to pick up on the fear of the language around disability. “Disability” covers a vast spectrum of lived experiences, and it’s okay to say the word. Sometimes, discomfort with the language can mask this diversity. I am registered legally blind, but my experience is incomparable to those of others. Eighty percent of disability is unseen, so unless there are what Yolanda describes as “safe spaces” for employees to self-declare disability, normalization is impossible. That’s why we need to demystify these terms through meaningful conversations and accessible services that elevate those voices.

Tim Hill: These perspectives can also be platformed in ways that offer more human connection. One of our HR analysts, Keigo Tozawa—also a member of our Americas DEI workgroup—underwent inclusive leadership training and experiential learning at OMRON Taiyo in Kyushu, Japan. He discovered a system started by a mentally disabled employee who struggled with expressing himself: workers would write their daily feelings and concerns on a whiteboard, in a highly visible area on the factory floor. This exercise helped employees relate to one another and was a valuable best practice shared with our workgroup. That’s why disabilities shouldn’t be magnified as weaknesses. We encourage all employees to transform their unique potential into value through mutual knowledge, cooperation and ingenuity.

How does inclusivity drive business outcomes?

YB: We see this not only from a business perspective, but a societal one. Some governments and organizations are trying to bring disabled people to the table. At the same time, OMRON has been pioneering inclusivity for over 50 years—it’s a collaboration between business and society.

CC: What business values and includes, society follows. There is no chance that we’re going to end the exclusion crisis without organizations like OMRON because when they share what they’re willing to learn from us, that will trickle into society. Business is the most powerful force for change on this planet, and you can’t force integration unless companies understand the value. The consumer spending power in this market is $13 trillion. Leaders are realizing that to serve those markets and as a point of growth and differentiation, they need this talent in their ranks.

To read the entire article please go to the WSJ Page linked here.

Shiitake vs Streptococcus pyogenes

Japanese follows below. 日本語は英文下に。

The highly contagious bacteria that cause the infection can, in some cases, cause serious illnesses, health complications and death, particularly in adults over 30. About 30% of STSS cases are fatal

Left: Shiitake cultivation at Mori Sangyo KK, Kiryu, Japan (Photo by the author); Right: S. pyogenes, (Photo: NAIAID, Wikimedia Commons)

“Experts warn that a rare but dangerous bacterial infection is spreading at a record rate in Japan, with officials struggling to identify the cause.

The number of cases in 2024 is expected to exceed last year’s record numbers, while concern is growing that the harshest and potentially deadly form of group A streptococcal disease – streptococcal toxic shock syndrome (STSS) – will continue to spread, after the presence of highly virulent and infectious strains were confirmed in Japan” – J. McCurry, Mystery in Japan as dangerous streptococcal infections soar to record levels, The Guardian (2024). https://www.theguardian.com/world/2024/mar/15/japan-streptococcal-infections-rise-details.

This form of Strep A is a nasty one. In his Guardian article (June 15th, 2024) Justin writes:

“Most cases of STSS are caused by a bacterium called streptococcus pyogenes. More commonly known as strep A – it can cause sore throats, mainly in children, and lots of people have it without knowing it and do not become ill. But the highly contagious bacteria that cause the infection can, in some cases, cause serious illnesses, health complications and death, particularly in adults over 30. About 30% of STSS cases are fatal”.

Across the globe, as drug-resistant pathogenic microorganisms proliferate, medicinal mushrooms (MMs) are being researched as never before as weapons in the fight against disease. In in vitro testing, a component derived from the edible shiitake mushroom has shown antimicrobial effectiveness against Streptococcus pyogenes to a degree that matches antimicrobial drugs.

Shiitake cultivation in the labs at Mori Sangyo KK, Kiryu, Japan. (Photos: JFA)

A 2001 paper from Hungary suggests the effetive substance is likely lenthionine. “The mycelium-free culture fluid [derived from Lentinus edodes, Shiitake] was bacteriostatic against Streptococcus pyogenes, Staphylococcus aureus and Bacillus megaterium. The substance responsible for the activity was heat-stable, could be extracted with chloroform and had a molecular weight under 10000. These characteristics suggested that the component might be lenthionine, an antibacterial and anti-fungal sulphur-containing compound”.

The paper then reassuringly adds “The culture fluid was less toxic to human tissue culture cells than to microbes.”

The following, from research conducted in Ireland in 2009, indicates the humble shiitake’s usefulness in a number of antimicrobial applications: “Several batches of Shiitake and oyster mushrooms were purchased fresh from a local supermarket and underwent aqueous extraction of potential antimicrobial components. After reconstitution, aqueous extracts were tested qualitatively against a panel of 29 bacterial and 10 fungal pathogens, for the demonstration of microbial inhibition. Results: Our data quantitatively showed that Shiitake mushroom extract had extensive antimicrobial activity against 85% of the organisms it was tested on, including 50% of the yeast and mould species in the trial. This compared favourably with the results from both the Positive control (Ciprofloxacin).”

J. R. Rao, B. C. Millar, J. E. Moore, Antimicrobial properties of shiitake mushrooms (Lentinula edodes). International Journal of Antimicrobial Agents 33, 591–592 (2009).

Shiitake offer other health benefits too. Lentinan is a polysaccharide extracted from Shiitake. β-Glucan is its major bioactive component, and has proven immunostimulatory effect. Its antitumor properties were recorded in the 1960s and it has been approved as an adjuvant therapeutic drug in China and Japan for treating cancers since 1980s. However, globally more often than not products derived from MMs – shiitake included – are marketed as ‘dietary supplements’.

Read more about its likely anti-tumor, cholesterol-lowering, immunostimulant, antiviral and antibacterial properties at the excellent, ever erring-on-the-side-of-caution, Memorial Sloan Kettering Cancer Center’s About Herbs site.

I’m lucky enough to live in Japan where there is a cheap and plentiful supply of Shiitake. I will make a decoction – aka, aqueous extract/fabulous dashi – and a tincture soon, and post more info here in case you’d like to try it yourself.

シイタケ対化膿レンサ球菌

希少だが危険な細菌感染症が日本で記録的な勢いで蔓延していると専門家が警告しています。 A群溶血性レンサ球菌感染症の中でも最も過酷で死に至る可能性のある「溶連菌中毒性ショック症候群(STSS)」が日本で確認されたことで、2024年の患者数は昨年の記録数を上回ると予想されています。

このA型溶連菌は厄介なものです。ジャスティンはガーディアンの記事(2024年6月15日)でこう書いています:

「STSSのほとんどは、化膿レンサ球菌と呼ばれる細菌によって引き起こされます。一般的には溶連菌Aとして知られているこの細菌は、主に子供たちの咽頭炎を引き起こします。しかし、この感染症の原因となる感染力の強い細菌は、特に30歳以上の成人では、場合によっては重篤な病気や健康合併症、死亡を引き起こすことがあります。STSSの約30%は死に至ります」。J. McCurry, Mystery in Japan as dangerous streptococcal infections soar to record levels, The Guardian (2024). https://www.theguardian.com/world/2024/mar/15/japan-streptococcal-infections-rise-details.

世界中で薬剤耐性の病原性微生物が増殖する中、薬用キノコ(MM)は病気と闘うための武器として、かつてないほど研究が進められています。化膿連鎖球菌の場合、実験室でのテストでは、地味なシイタケ由来の成分が抗菌効果を示しました。

以下は、2009年にアイルランドで行われた研究によるもので、地味なシイタケが多くの抗菌用途に有用であることを示しています:

2001年にハンガリーで発表された論文によると、これはレンチオニンかもしれません。「菌糸体を含まない培養液(Lentinus edodes, Shiitake由来)」は、Streptococcus pyogenesStaphylococcus aureusBacillus megateriumに対して静菌性を示しました。活性の原因物質は熱に強く、クロロホルムで抽出でき、分子量は10000以下でした。これらの特徴から、この成分は抗菌・抗真菌性の含硫化合物であるレンチオニンである可能性が示唆されました」。

そして、この論文は、”培養液は、微生物よりもヒト組織培養細胞に対する毒性が低かった “と付け加えています。

地元のスーパーマーケットから新鮮なシイタケとヒラタケを数バッチ購入し、内在する抗菌成分を水抽出しました。再構成後、水性抽出物を29種類の細菌および10種類の真菌病原体パネルに対して定性試験を行い、微生物阻害を実証しました。その結果、シイタケ抽出物は、試験対象となった酵母およびカビ種の50%を含む85%の生物に対して、広範な抗菌活性を有することが定量的に示されました。これは、陽性対照(シプロフロキサシン)の結果と比較すると、良好な結果でした。J. R. Rao, B. C. Millar, J. E. Moore, Antimicrobial properties of shiitake mushrooms (Lentinula edodes). International Journal of Antimicrobial Agents 33, 591–592 (2009).

シイタケには他にも健康効果があります。レンチナンはシイタケから抽出される多糖類です。β-グルカンはその主要な生理活性成分で、免疫賦活作用が証明されています。その抗腫瘍作用は1960年代に記録され、1980年代以降、中国や日本ではがんの補助治療薬として承認されています。しかし、世界的には、シイタケを含むMM由来の製品は、「栄養補助食品」として販売されることが多くなっています。 抗腫瘍作用、コレステロール低下作用、免疫賦活作用、抗ウイルス作用、抗菌作用については、メモリアル・スローン・ケタリングがんセンターの「ハーブについて」のサイトをご覧ください。

私は幸運にも日本に住んでいて、安くて豊富なシイタケが手に入ります。近々、煎じ薬とチンキを作る予定です。@medicinalmushrooms @fungi @Japan @fungiJapan

Sano Shuji, our Great Mushroom Teacher

Sano-san is our great friend and ‘shishō’ 師匠- the Master – of all things fungi. Check out my story in Kyoto Journal, issue 104, ‘A Fascination with Fungi’, or drop by the Kyoto Imperial Palace Gardens once a month to join Sano-san on one of his brilliant Sunday morning fungi forays. Mrs A. and I are usually there. There is a Japanese translation of the text included, if you wish to show it to a Japanese friend (or are Japanese yourself 笑).

Sano-san will also be leading a Mushroom hunt to coincide with the Kansai Mycological Club’s 30th annual mushroom event on Saturday 28th October from 2 to 3 pm in the Kyoto Botanical Gardens . I’ll be at the venue providing English translation, though likely in the main exhibition space, not Sano-san’s lecture.

Dates: October 28 (Saturday) to October 29 (Sunday), 9:00 a.m. to 5:00 p.m. (until 4:00 p.m. on the last day). Why not bring along a mushroom or two and get it identified by the experts.

The following pics are from the Botanical Gardens event in 2019:

This is one of the Sunday-morning Kyoto Imperial Gardens forays led by Sano Shuji:

Kew Releases State of the World’s Plants and Fungi 2023 & Global Fungal Review

State of the World’s Plants and Fungi 2023/plus open-access, global review of fungal diversity

[October 11th, 2023] Kew writes: Our fifth report in the State of the World’s series lays out the current condition of the world’s plants and fungi globally, and is titled ‘Tackling the Nature Emergency: Evidence, gaps and priorities’

It is the second report that is accompanied by a full volume of expert-reviewed scientific publications from our partners, the New Phytologist Foundation. Their special collection on ‘Global Plant Diversity and Distribution’ includes open-access papers published in the journals New Phytologist and Plants, People, Planet

In parallel, an open-access, global review of fungal diversity is published in the Annual Review of Environment and Resources. More info here: https://www.kew.org/science/state-of-the-worlds-plants-and-fungi Twitter link to Kew Mycology here: https://twitter.com/kewscience/status/1711676629380923597?s=12&t=R0_LjyTJmE7FJQt-GVxvVg

You can download the SOWPAF 2023 PDF here

The Global Fungal Review paper PDF may be downloaded here:

Myco/Health Benefits of Reishi: the Short(-ish) Version

The list of suggested health benefits for the Ganoderma lucidum fungus is huge. I have dozens of academic papers, and less formal articles, on the topic. Here I’m posting just a few, to give an overall impression for the readers who don’t want to pore over volumes stuffed with complex terminology (I confess, I like that stuff).

I’m also including, for balance, the entry for Reishi at the Memorial Sloan Kettering Hospital excellent ‘About Herbs’ site. They are at the cautious, objective end of the evaluation scale. But we begin with a table from the ultimate Medicinal mushroom advocate, Paul Stamets. This is from his Host Defense Mushrooms commercial site.

Reishi 霊芝 aka マンネンタケ aka Ganoderma lucidum, here in Kyoto, September 2023.

A quick glance at my notes reveals that the following Medicinal attributes apply to Reishi (it’s not an exhaustive list): Anti-aggregant; Anti-allergy; Anti-bacterial; Anti-herpetic (it’s used against herpes); Anti-inflammatory; Anti-oxidant; Anti-tumour (boosts NK (natural killer) cells; Anti-ulcer; Anti-viral (it’s in the anti-HIV ‘cocktail’); Cholesterol lowering; Hepatoprotective and Anti-Hepatosis (liver protect and heal); Immunomodulating; Lowers serum glucose (Anti-diabetic); works against Colitis/IBD.

Naturally, these claims are extremely difficult to prove.  Most of the research is in vitro, and it’s hard to prove that these effects work outside the lab. That said, if ‘follow the money’ being chucked at Reishi research across the globe, it is quite astounding. Here is just one example of the cross-border collaboration taking place:

Certainly Ganoderma lucidum – known as Linghzi in China – plays an important role in TCM (Traditional Chinese Medicine) though this excellent piece in the North American Mycological Journal argues strongly that its ‘ancient history’ is based more on speculation than actual fact. “Belief in the antiquity of use is somehow supposed to make this polypore more acceptable as a an empirically verified scientific medicine,” argues author Dianna Smith, “. “This is unfortunate. Certainly, there are numerous fungi used in Chinese cooking, which are also recommended for maintaining health and even enhancing it if not in tip-top shape. However, it is impossible to find supporting evidence that Ganoderma ling zhi has a two to seven-thousand-year history of use in China”.

One thing is for sure, the Chinese are buying Reishi like never before. Indeed so is everyone. One study reports a market value of 104.78M USD by 2025 for Reishi mushroom extract (www.marketwatch.com).

Memorial Sloan Kettering reins in some of the more extreme claims, and advises ‘more research is necessary’. Here’s their synopsis for ‘patients and caregivers’. They add the text below, ‘for health care professionals’ (warning, nerdy science language follows):

Beta glucans, polysaccharides present in reishi, demonstrated antitumor and immunostimulating activities (18) (40). Its triterpene compounds may inhibit tumor invasion by reducing matrix metalloproteinase expression (16), and tumor metastases by limiting attachment to endothelial cells (17). Findings also indicate that reishi induces natural killer (NK) cell cytotoxicity against various cancer cell lines via activation of the natural cytotoxic receptors (NKG2D/NCR) and mitogen-activated protein kinase (MAPK)-signaling pathways, which result in exocytosis of perforin and granulysin (31). Reishi polysaccharides were shown to increase expression of the major histocompatibility (MHC) class I and costimulatory molecules on melanoma cells, resulting in enhanced antitumor cytotoxicity (32). In ovarian cancer cells, reishi induced G2/M phase cell cycle arrest, activated caspase 3 to induce apotosis, increased p53, and inhibited Akt expression (27).

Finally, here’s a link to the multi-nation 2023 paper on Ganoderma lucidum briefly mentioned above: https://www.mdpi.com/2304-8158/12/7/1512

Intro to JTA Sightseeing Database 観光資源情報データベース/Kizakura (Kizakura Co. Ltd.) and Kappa Country

The Japan Tourism Agency (JTA) Sightseeing Database is a great resource (searchable, in Japanese too) if you don’t mind the lack of fancy pictures. The link to their main page is here. 日本語リンクはここです I’ve been writing pieces for them for several years now. My locations have included a World Heritage Site (Sericulture in Gunma), a National Park (Kamikochi and environs, Gifu/Nagano), a Samurai Town and Geopark (Hagi, Yamaguchi), and Sake Breweries and Historical Sites (Fushimi, Kyoto), amongst others.

In their words: “The Japan Tourism Agency (JTA) has set up this website for searching English-language texts on sightseeing destinations in Japan. The texts, totaling around 7,000, have been prepared for the JTA’s “Promoting Multilingual Support for Sightseeing Destinations around Japan” project. The objective of the database is to provide regions in Japan and the private sector with content they can use to supplement or refer to for creating their own texts for media, such as interpretive signs, pamphlets, and websites”.

Have a poke around to see what takes your fancy. Here’s one example of some of my stuff.日本語のテキストは以下の英文に続く

Kizakura (Kizakura Co. Ltd.) and Kappa Country

A relative newcomer to the Fushimi sake scene, Kizakura was founded in 1925 by Matsumoto Jirokurō (dates unknown) when he split off from his family’s brewery. Unlike most of the breweries in Fushimi today, Kizakura also brews beer.

In 1995 the company established Kizakura Kappa Country in its old brewery buildings to showcase its products and explain the company’s history. Traditional straw-wrapped barrels are stacked at the entrance. These bear the company emblem, Kizakura—literally “yellow cherry blossom.” A garden patio contains tables and features a cherry tree with yellow springtime blooms.

Photo by me, added, not in JTA original.

One old sake warehouse has been converted into a small museum that explains the origin of Fushimi sake and displays posters showing how the company has developed since its founding. In the first room, a small diorama illustrates ancient brewing techniques, from the first washing of the rice to thepressing that separates the finished sake from the lees.

In one corner of the room, there is a faucet that draws directly from a natural spring called Fushimizu. All of the beer and sake made at Kizakura is made with this spring water. By tradition, the springs of Fushimi are open to the public.

In the next room an old wooden sake press (sakafune) is on display. On the other side of a glass panel is its twenty-first century equivalent, capable of doing many times the work in a fraction of the time.

©JTA Sightseeing database, created 2019 https://www.mlit.go.jp/tagengo-db/en/R1-01265.html

Associated Address:228 Shioyamachi, Fushimi-ku Kyoto-shi , Kyoto

Japanese here: 黄桜(黄桜酒造株式会社)とカッパカントリー

伏見の酒処の比較的若い企業である黄桜は、1925年に松本治六郎(生没年非公開)が一族の蔵元から独立し設立された。 今日の伏見のほとんどの蔵元とは異なり、黄桜はビールも醸造している。

1995年、同社は製品を紹介し、会社の歴史を説明するために、古い蔵元の建物内に黄桜カッパカントリーを設立した。 伝統的なわらで包まれた樽が入り口に積み重ねられている。樽には会社の徽章である黄桜が付いている — 文字通り「黄色い桜」である。庭のパティオにはテーブルがあり、春に咲く黄色い桜が見所になっている。

古い酒蔵の1つは、伏見の日本酒の起源を説明する小さな博物館に改築され、創業以来の会社の発展を示すポスターが展示されている。 最初の部屋の小さなジオラマには、米を最初に洗うことから、完成した日本酒をかすから分離する圧搾まで、古代の醸造技術が展示されている。

部屋の片隅には、伏水と呼ばれる天然の泉から直接引き出される蛇口がある。 黄桜で作られるビールと日本酒はすべてこの湧水で作られている。 伝統的に、伏見の湧水は一般に開放されている。

隣の部屋には、古い木製の酒槽搾り(酒舟)が展示されている。 ガラスパネルの反対側には、21世紀の同じ機械に相当するものがあり、何分の一かの時間で何度も作業を行うことができる。

How to Make Simple Medicinal Mushroom Extracts (part two – the water decoction)

On Your Mark, Get Set, Boil and Simmer

This is second part of the method described in an earlier post,  what is known as a double or dual extraction.

To recap, we are looking at a duel extraction process here, with two steps, using alcohol and water. That is to say, steeping the mushrooms in alcohol (making a tincture) and boiling the mushrooms in water (making a decoction). You can do this with the same batch of mushrooms. Indeed, this is the least wasteful approach, and the most cost effective. You get more out of your mushrooms this way.

However, if you decide to make a tincture with one batch of mushrooms, and a decoction with another set of mushrooms – the other half of your harvest, perhaps – and keep them separate, that’s fine too.

Making the decoction

To begin your ‘marc’, the mushrooms left over from the alcohol soak, or fresh mushrooms, and soak them in water in a large pot. If you are using fresh mushrooms, make sure to scrub off as much dirt – and bugs – as possible. I generally rinse fresh mushrooms, soak them in water for a while, then dry them overnight in my drier. This stops any moud creeping in. The green meanies seem to go for reishi as soon as you bring them out of the forest. Here’s what my drying process looks like:

As you’ll not, I sliced these reishi up to dry. They were pretty tough, so it took some effort. I used a saw, a chisel and finally scissors to get them down to size. Younger specimens are easier to slice.

Boiling/Simmering and a Recipe

A quick net search will show you that there are many different recommendations for how long to heat the mixture. I follow my Japanese ‘Mushroom master’ Shuji Sano’s advice.

  • Take 50 grammes of Medicinal mushrooms
  • Add them 2 litres of water in a large saucepan
  • Bring to a boil, then reduce to a simmer
  • Let the mixture simmer for an hour, or until the liquid has reduced by half
  • Filter off the liquid (I use a kitchen drain net)
  • Et voila, you have a litre of Medicinal mushroom decoction.

Sano-san combines 40 grammes of Reishi (Ganoderma lucidum) with 10 grammes of Artist’s Conk (Ganoderma applanatum). How you take it is up to you. Mrs A and I add 25 ml to our morning smoothies, along with several drops of the Medicinal mushroom tincture mentioned previously.

Kew Mycology/Gay Icons as Fungi

Or is that Fungi as gay Icons? To celebrate Pride Month in the UK, the Kew Gardens Mycology department came up with these fun images. Which is your favourite?

Smart Cities (WSJ/The Trust)

Here’s something I wrote for Wall Street Journal’s content division, The Trust, for those of you with an interest in such things.

World Food Japan (Amazon page)

I spent a long time writing this book. When it dropped through the letter box I was amazed. “Who the x@#! is Yoshi Abe?” I shouted. Despite some awful editing by LP I am still proud of it. Great assistance from Mrs A throughout. If anyone else’s name was to be on it, it should have been hers.

It seems that some people liked it, according to the reviews:

It also seems that I am a real person and have a brain!